糖蛋白药物在多种疾病中显示出靶点特异、疗效突出和安全性好等优点，其糖基化是影响药物半衰期、免疫原性和药代动力学等的重要因素.糖工程促进糖蛋白药物上糖链的改造和优化研究逐渐深入.本文简述重组糖蛋白药物在细胞内或体外的合成和糖链改造，并指出生产均一化糖蛋白是研究糖链对药物性质影响的前提和基础.
Therapeutic glycoproteins show the advantages of specificity, outstanding curative effect, and good safety in many diseases. Glycosylation is an important factor affecting molecular stability, immunogenicity, and pharmacokinetic profiles. By means of glycoengineering strategies, researches on the evolution of glycan on therapeutic glycoproteins have deepened. This paper briefly describes the production and modification of recombinant glycoproteins in vivo or vitro, and indicates that the production of homogeneous glycoprotein is the prerequisite for studying the effect of glycan on therapeutic glycoprotein properties.
［1］MIZUKAMI A, CARON A L, PICANO-CASTRO V, et al. Platforms for recombinant therapeutic glycoprotein production［J］. Methods in Molecular Biology, 2018, 1674: 1-14.
［2］SOL R J, GRIEBENOW K. Glycosylation of therapeutic proteins: An effective strategy to optimize efficacy［J］. BioDrugs, 2010, 24(1): 9-21.
［3］VARKI A. Biological roles of glycans［J］. Glycobiology, 2017, 27(1): 3-49.
［4］MA B, GUAN X, LI Y, et al. Protein glycoengineering: An approach for improving protein properties［J］. Frontiers in Chemistry, 2020, 8: 622.
［5］HOKKE C H, BERGWERFF A A, VAN DEDEM G W K, et al. Sialylated carbohydrate chains of recombinant human glycoproteins expressed in Chinese hamster ovary cells contain traces of N-glycolylneuraminic acid［J］. FEBS Letters, 1990, 275(1/2): 9-14.
［6］YAMANE-OHNUKI N, KINOSHITA S, INOUE-URAKUBO M, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity［J］. Biotechnology and Bioengineering, 2004, 87(5): 614-622.
［7］NARIMATSU Y, JOSHI H J, NASON R, et al. An atlas of human glycosylation pathways enables display of the human glycome by gene engineered cells［J］. Molecular Cell, 2019, 75(2): 394-407.
［8］VALDERRAMA-RINCON J D, FISHER A C, MERRITT J H, et al. An engineered eukaryotic protein glycosylation pathway in Escherichia coli［J］. Nature Chemical Biology, 2012, 8(5): 434-436.
［9］RICH J R, WITHERS S G. Emerging methods for the production of homogeneous human glycoproteins［J］. Nature Chemical Biology, 2009, 5(4): 206-215.
［10］GIDDENS J P, LOMINO J V, DILILLO D J, et al. Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody［J］. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115(47): 12023-12027.
［11］WU Z G, JIANG K, ZHU H L, et al. Site-directed glycosylation of peptide/protein with homogeneous O-linked eukaryotic N-glycans［J］. Bioconjugate Chemistry, 2016, 27(9): 1972-1975.
［12］XU Y Y, WU Z G, ZHANG P R, et al. A novel enzymatic method for synthesis of glycopeptides carrying natural eukaryotic N-glycans［J］. Chemical Communications, 2017, 53(65): 9075-9077.
［13］BUETTNER M J, SHAH S R, SAEUI C T, et al. Improving immunotherapy through glycodesign［J］. Frontiers in Immunology, 2018, 9: 2485.
